

Santhera reports preliminary key financial figures for 2014

Liestal, Switzerland, January 23, 2015 – Santhera Pharmaceuticals (SIX: SANN) today announced preliminary, unaudited key financial figures for 2014. For the reporting period, the Company increased revenues and made significant progress in all product development programs.

- In 2014, the Company reported increased net sales of CHF 2.6 million (2013: CHF 1.3 million) from sales of Raxone[®]. These sales originated from international Named Patient Programs as well as first product sales for patients with Leber's Hereditary Optic Neuropathy (LHON) under the temporary authorization for use (ATUc) granted in France. This ATUc was recently renewed for 2015.
- Together with financing in the aggregate gross amount of CHF 15.7 million Santhera had CHF 17.4 million in cash and cash equivalents by end of 2014 (December 31, 2013: CHF 5.0 million).
- As a result of the financings and option exercises in 2014, and with effective date January 28, 2015, the Company's outstanding shares entered into the commercial register will amount to 4,974,492.

Thomas Meier, PhD, Chief Executive Officer of Santhera commented: "We are very excited about Santhera's development last year. Financially, we benefitted from income from share placements and increasing revenues from product sales. We are particularly pleased about the product acceptance and enrolment of LHON patients under the French ATUc protocol for Raxone. The Company made tremendous progress in all development and regulatory activities.

In the first half of 2015, we are expecting the opinion from the Committee for Medicinal Products for Human Use (CHMP) on our European marketing authorization application for Raxone in LHON which could become the first product authorized for the treatment of this disease. Based on the successful outcome of the Phase III trial in Duchenne Muscular Dystrophy, we also currently prepare for regulatory filings for this indication both in the US and Europe."

Upcoming corporate events:

- Release of the audited financial results for 2014 on April 14, 2015
- Annual Shareholder's Meeting on May 20, 2015

Santhera reports preliminary key financial figures for 2014

January 23, 2014 / Page 2 of 2

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera develops Catena[®]/Raxone[®] as treatment for patients with Leber's Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD) and Primary Progressive Multiple Sclerosis (PPMS) and omigapil for Congenital Muscular Dystrophies (CMD), all areas of high unmet medical need for which no therapies are currently available. For further information, please visit the Company's website www.santhera.com.

Raxone[®] and Catena[®] are trademarks of Santhera Pharmaceuticals.

For further information, contact:

Thomas Meier, Chief Executive Officer
Phone +41 61 906 89 64
thomas.meier@santhera.com

US Investor contact:

Andrew McDonald
LifeSci Advisors, LLC
Phone +1 646 597 6979
andrew@lifesciadvisors.com

Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

###